Results 41 to 50 of about 960 (168)

Supplementary Figure S4 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Recursive feature elimination with cross-validation of Coxnet model using fragmentomics ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Supplementary Figure S2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Different cross-validation results of Coxnet model using fragmentomics ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Supplementary Figure S1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Evaluating longitudinal fragmentomics model prediction and ctDNA ...
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay [PDF]

ESMO Open
H Bao
exaly   +2 more sources

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

Molecular Oncology, 2022
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit.
Daan C. L. Vessies, Milou M. F. Schuurbiers, Vincent van derNoort, Irene Schouten, Theodora C. Linders, Mirthe Lanfermeijer, Kalpana L. Ramkisoensing, Koen J. Hartemink, Kim Monkhorst, Michel M. van denHeuvel, Daan van denBroek   +10 more
doaj   +1 more source

Table S1-2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

, 2023
Supplementary Table S1. Patient demography Supplementary Table S2. Evaluating fragmentomics model performances and ctDNA mutation-based method.
Xue Wu (15004506), Zhijun Xia (15491857), Wanxiangfu Tang (15491872), Jing You (15491860), Siwei Wang (15491854), Jie Wang (15491884), Fanchen Meng (15491866), Yang Shao (15491881), Jingyuan Zhang (15491878), Xianglin Zuo (15491887), Lin Xu (15491890), Peng Chen (15491869), Xiaolan Gu (15491863), Rong Yin (15491893), Hua Bao (15491875)   +14 more
core   +1 more source

Detecting Liver Cancer Using Cell-Free DNA Fragmentomes

Cancer Discovery, 2022
Abstract Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved survival, but current screening methods are inadequate.
Zachariah H. Foda, Akshaya V. Annapragada, Kavya Boyapati, Daniel C. Bruhm, Nicholas A. Vulpescu, Jamie E. Medina, Dimitrios Mathios, Stephen Cristiano, Noushin Niknafs, Harry T. Luu, Michael G. Goggins, Robert A. Anders, Jing Sun, Shruti H. Meta, David L. Thomas, Gregory D. Kirk, Vilmos Adleff, Jillian Phallen, Robert B. Scharpf, Amy K. Kim, Victor E. Velculescu   +20 more
openaire   +2 more sources

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response [PDF]

Genomics, Proteomics and Bioinformatics
Lijun Dai, Jiaqi Liu
exaly   +2 more sources

Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients

EMBO Molecular Medicine, 2021
Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because quantities in body fluids are low. We determined the glioma‐derived DNA fraction in cerebrospinal fluid (CSF), plasma, and urine samples from patients using ...
Florent Mouliere, Christopher G Smith, Katrin Heider, Jing Su, Ymke van der Pol, Mareike Thompson, James Morris, Jonathan C M Wan, Dineika Chandrananda, James Hadfield, Marta Grzelak, Irena Hudecova, Dominique‐Laurent Couturier, Wendy Cooper, Hui Zhao, Davina Gale, Matthew Eldridge, Colin Watts, Kevin Brindle, Nitzan Rosenfeld, Richard Mair   +20 more
doaj   +1 more source

Cell-free DNA fragmentomics: a universal framework for early cancer detection and monitoring. [PDF]

Am J Clin Exp Immunol
Cell-free DNA (cfDNA) fragmentomics has emerged as a powerful and noninvasive approach for cancer detection, characterization, and monitoring. By analyzing genome-wide fragmentation patterns - including fragment length distributions, end motifs, nucleosome footprints, and copy number variations - cfDNA fragmentomics provides high-resolution insights ...
Dong W, Hu W, Lu Y, Zheng Q.
europepmc   +3 more sources